Testing vismodegib plus atezolizumab for platinum-resistant ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests whether combining vismodegib with atezolizumab can slow or shrink platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It targets cancers that grow again within 6 months after platinum chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to sign the study consent form and follow the study plan.
- You have confirmed epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Your cancer must have progressed during or within 6 months after platinum chemotherapy.
- You need a follow-up plan for your cancer measurements (measurable or evaluable disease).
- Your body must be able to handle treatment based on blood tests and organ function (recent lab results within 14 days).
- You must be able to swallow capsules and avoid pregnancy during treatment and the required follow-up period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, vismodegib and atezolizumab, for people with non-small cell lung cancer that has spread or come back after standard treatments. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two targeted drugs, EZH2 inhibitor and PARP inhibitor, for people with advanced or recurrent epithelial ovarian cancer that does not have BRCA1/2 gene mutations. The goal is to see if this combination can shrink tumors or slow the disease.
This trial compares a combination of two drugs (sacituzumab govitecan and bevacizumab) to standard chemotherapy for ovarian cancer that has come back after treatment with a PARP inhibitor. It is for people whose cancer has a BRCA mutation or is homologous recombination deficient.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), a targeted therapy (bevacizumab), and a PARP inhibitor (fluzoparib) for ovarian cancer that came back at least 6 months after last platinum chemo. It aims to see if this mix helps control the cancer better.
This trial tests a new combination of drugs for ovarian cancer that has come back quickly after platinum-based chemo. The goal is to see if adding an immunotherapy and a targeted pill to non-platinum chemo can help shrink tumors.
Hear when a new Platinum-Resistant Fallopian Tube Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.